Hypersensitivity reactions to biologics (part II): classifications and current diagnostic and treatment approaches

作者: Askin Gülsen , Bettina Wedi , Uta Jappe

DOI: 10.1007/S40629-020-00127-5

关键词:

摘要: Biotechnological substances (BS) have rapidly expanded their clinical use. In parallel, there is an increase in expected or unexpected immunological non-immunological adverse effects. this part of the review, current nomenclature BSs, classification hypersensitivity reactions (HSR), as well diagnostic and treatment approaches are documented to provide tools understand used throughout databases need harmonize it where applicable. Detailed searches were performed on Pubmed, Web Science, Google Scholar include all available publications. The search terms, such specific BS, allergy, anaphylaxis, hypersensitivity, reactions, classification, diagnosis, grading, management, desensitization, determined for search. Case reports, articles, reviews subject included. Today, a variety non-standardized methods support diagnosis. These prick-to-prick tests intradermal with drug itself its potentially allergenic ingredients. More rarely, anti-drug antibodies detected basophil activation by centers research facilities. Although protocols acute conditions vary, overall approach same. HSRs BS gradually increasing widening use indications. It very important prevent know degree severity emergency algorithm. This review summarizes that should be applied: (a) immediately during/after a reaction, (b) subsequently, case a switch not possible, desensitization option.

参考文章(79)
Pedro Giavina-Bianchi, Marcelo Vivolo Aun, Violeta Régnier Galvão, Mariana Castells, Rapid Desensitization in Immediate Hypersensitivity Reaction to Drugs Current Treatment Options in Allergy. ,vol. 2, pp. 268- 285 ,(2015) , 10.1007/S40521-015-0060-2
Dana L. Baker, Gerald R. Nakamura, Henry B. Lowman, Saloumeh Kadkhodayan Fischer, Evaluation of IgE Antibodies to Omalizumab (Xolair®) and Their Potential Correlation to Anaphylaxis Aaps Journal. ,vol. 18, pp. 115- 123 ,(2016) , 10.1208/S12248-015-9821-X
Johannes Ring, Kirsten Beyer, Tilo Biedermann, Andreas Bircher, Dorothea Duda, Jörg Fischer, Frank Friedrichs, Thomas Fuchs, Uwe Gieler, Thilo Jakob, Ludger Klimek, Lars Lange, Hans F. Merk, Bodo Niggemann, Oliver Pfaar, Bernhard Przybilla, Franziska Ruëff, Ernst Rietschel, Sabine Schnadt, Roland Seifert, Helmut Sitter, Eva-Maria Varga, Margitta Worm, Knut Brockow, Guideline for acute therapy and management of anaphylaxis Allergo journal international. ,vol. 23, pp. 96- 112 ,(2014) , 10.1007/S40629-014-0009-1
Arne Homann, Niels Röckendorf, Arno Kromminga, Andreas Frey, Uta Jappe, B cell epitopes on infliximab identified by oligopeptide microarray with unprocessed patient sera Journal of Translational Medicine. ,vol. 13, pp. 339- 339 ,(2015) , 10.1186/S12967-015-0706-7
Román Peréz-Soler, Leonard Saltz, Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? Journal of Clinical Oncology. ,vol. 23, pp. 5235- 5246 ,(2005) , 10.1200/JCO.2005.00.6916
Wendy H. Vogel, Infusion reactions: diagnosis, assessment, and management. Clinical Journal of Oncology Nursing. ,vol. 14, ,(2010) , 10.1188/10.CJON.E10-E21
Andreas Stallmach, Thomas Giese, Carsten Schmidt, Stefan C Meuer, Stefan S Zeuzem, Severe anaphylactic reaction to infliximab: successful treatment with adalimumab - report of a case. European Journal of Gastroenterology & Hepatology. ,vol. 16, pp. 627- 630 ,(2004) , 10.1097/00042737-200406000-00018
Emanuele Sinagra, Giovanni Perricone, Claudia Romano, Mario Cottone, Heart failure and anti tumor necrosis factor-alpha in systemic chronic inflammatory diseases European Journal of Internal Medicine. ,vol. 24, pp. 385- 392 ,(2013) , 10.1016/J.EJIM.2012.12.015
Laura Somerville, Jose Bardelas, Andrea Viegas, Peter D’Andrea, Martin Blogg, Guy Peachey, Immunogenicity and safety of omalizumab in pre-filled syringes in patients with allergic (IgE-mediated) asthma Current Medical Research and Opinion. ,vol. 30, pp. 59- 66 ,(2014) , 10.1185/03007995.2013.844115